Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

SpainBack to Spain

Clinical trials in Badajoz – page 8

115 clinical trials in Badajoz, Spain. Every trial is listed in the EU Clinical Trials Register and updated daily.

SpainOur site in SpainEnsayosClinicos.es(opens in a new tab)
Badajoz at a glance
115
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

115 trials in Badajoz

Open in trial search

Hormone receptor positive HER2 negative breast cancer

Not recruiting

Study Comparing Ribociclib and Palbociclib for Patients with Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Palbociclib
  • Sponsor:Solti Group

Non-small cell lung cancer metastatic

Not recruiting

Study on Inupadenant, Carboplatin, and Pemetrexed for Adults with Metastatic Non-Small Cell Lung Cancer After Immunotherapy

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Inupadenant Hydrochloride
  • Sponsor:iTeos Belgium

Hormone receptor positive breast cancer+1

Not recruiting

Study on Diarrhea Discontinuations in Early-stage HER2+ Breast Cancer Patients Treated with Neratinib, Loperamide, and Colesevelam

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Neratinib
  • Sponsor:Fundacion Grupo Espanol De Investigacion En Cancer De Mama

Neoplasm

Not recruiting

Study of EOS884448, Dostarlimab, and Inupadenant for Patients with Advanced Solid Tumors

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Dostarlimab
  • Sponsor:iTeos Belgium

Ductal adenocarcinoma of pancreas

Not recruiting

Study of SBP-101, Nab-Paclitaxel, and Gemcitabine for Patients with Metastatic Pancreatic Cancer

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Gemcitabine
  • Sponsor:Panbela Therapeutics Inc.

Chronic hepatitis B

Not recruiting

Study on Bepirovirsen for Patients with Chronic Hepatitis B Receiving Nucleos(t)ide Analogue Treatment

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Bepirovirsen
  • Sponsor:Glaxosmithkline Research & Development Limited

Malignant melanoma stage IV+1

Not recruiting

Study of Nivolumab and Relatlimab for Patients with Stage III-IV Melanoma After Surgery

Registered drugNo placebo
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:Bristol Myers Squibb International Corporation

Breast neoplasm

Not recruiting

Study Comparing Abemaciclib and Fulvestrant with Placebo and Fulvestrant for Patients with Advanced or Metastatic Breast Cancer After Previous Treatment

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:Eli Lilly & Co.

Breast cancer

Not recruiting

Study on Olaparib for Patients with High-Risk HER2-Negative Breast Cancer and BRCA1/2 Mutations After Chemotherapy

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Olaparib
  • Sponsor:AstraZeneca AB

Hormone receptor positive breast cancer

Not recruiting

Study of OP-1250 for Treating Advanced or Metastatic ER+, HER2- Breast Cancer in Patients After Endocrine and CDK4/6 Inhibitor Therapy

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:Olema Pharmaceuticals Inc.

Breast cancer metastatic+1

Not recruiting

Study Comparing Trastuzumab Deruxtecan and Trastuzumab Emtansine for Patients with Advanced HER2-Positive Breast Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Trastuzumab Deruxtecan
  • Sponsor:Daiichi Sankyo Inc.

HER2 negative breast cancer

Not recruiting

Study on Olaparib for Patients with Advanced HER2-Negative Breast Cancer and Specific Genetic Mutations

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Olaparib
  • Sponsor:Solti Group

Other cities in Spain

The busiest research cities in the country

All 218 cities in Spain

Clinical research in Badajoz

What the registry says about research in the country

01 Oncology Research

Groundbreaking trials focusing on breast cancer treatments, including studies for HER2-positive, triple-negative, and hormone receptor-positive variants. Additional research explores novel therapies for bladder cancer and prostate cancer.

  • Advanced breast cancer treatments
  • Bladder cancer immunotherapy
  • Pancreatic cancer interventions
  • Colon cancer management

Studies evaluate combination therapies and novel drug applications for improved patient outcomes.

02 Metabolic Disorders

Innovative research targeting Type 1 Diabetes and obesity management. Studies investigate new therapeutic approaches for weight management and glycemic control in patients with multiple metabolic conditions.

  • Diabetes management
  • Obesity treatment
  • Cardiovascular safety studies

Focus on developing integrated treatment approaches for complex metabolic conditions.

03 Autoimmune Conditions

Comprehensive research into systemic lupus erythematosus and psoriatic arthritis, evaluating new therapeutic agents and treatment approaches for chronic autoimmune conditions.

  • Lupus treatment innovations
  • Arthritis management
  • Sjögren's syndrome therapy

Trials aim to improve long-term disease management and patient quality of life.

Back to SpainAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.